Citigroup
KPTI icon

Citigroup’s Karyopharm Therapeutics KPTI Stock Holding History

Citigroup’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.5K Buy
4,941
+4,940
+494,000% +$37.7K ﹤0.01% 4734
2025
Q4 		$7 Sell
1
-512
-100% -$3.13K ﹤0.01% 5837
2025
Q3 		$3.35K Sell
513
-6,527
-93% -$35.1K ﹤0.01% 5350
2025
Q2 		$30.3K Sell
7,040
-4
-0.1% -$20 ﹤0.01% 4974
2025
Q1 		$26.3K Sell
7,044
-1
-0% -$9 ﹤0.01% 5036
2024
Q4 		$71.5K Sell
7,045
-1
-0% -$12 ﹤0.01% 4969
2024
Q3 		$87.7K Sell
7,046
-3,756
-35% -$46.7K ﹤0.01% 4818
2024
Q2 		$141K Buy
10,802
+9,540
+756% +$158K ﹤0.01% 4056
2024
Q1 		$28.6K Buy
1,262
+167
+15% +$2.93K ﹤0.01% 4914
2023
Q4 		$14.2K Buy
1,095
+988
+923% +$13.3K ﹤0.01% 5099
2023
Q3 		$2.15K Sell
107
-2,443
-96% -$54.8K ﹤0.01% 4941
2023
Q2 		$68.5K Sell
2,550
-46,118
-95% -$1.99M ﹤0.01% 4452
2023
Q1 		$2.84M Buy
48,668
+14,762
+44% +$729K ﹤0.01% 1796
2022
Q4 		$1.73M Sell
33,906
-6,587
-16% -$457K ﹤0.01% 2155
2022
Q3 		$3.32M Buy
40,493
+9,225
+30% +$689K ﹤0.01% 1795
2022
Q2 		$2.12M Buy
31,268
+22,749
+267% +$2.09M ﹤0.01% 2062
2022
Q1 		$942K Sell
8,519
-11,754
-58% -$1.46M ﹤0.01% 3027
2021
Q4 		$1.96M Buy
20,273
+4,056
+25% +$404K ﹤0.01% 2641
2021
Q3 		$1.42M Sell
16,217
-9,718
-37% -$1.01M ﹤0.01% 2808
2021
Q2 		$4.01M Buy
25,935
+3,531
+16% +$512K ﹤0.01% 2100
2021
Q1 		$3.54M Buy
22,404
+21,232
+1,812% +$4.47M ﹤0.01% 2078
2020
Q4 		$272K Buy
1,172
+87
+8% +$20.2K ﹤0.01% 4750
2020
Q3 		$237K Sell
1,085
-7,989
-88% -$1.95M ﹤0.01% 4499
2020
Q2 		$2.58M Buy
9,074
+4,539
+100% +$1.34M ﹤0.01% 2514
2020
Q1 		$1.31M Buy
4,535
+2,704
+148% +$746K ﹤0.01% 2900
2019
Q4 		$526K Sell
1,831
-6,715
-79% -$1.46M ﹤0.01% 4377
2019
Q3 		$1.23M Buy
8,546
+6,800
+389% +$922K ﹤0.01% 3401
2019
Q2 		$157K Buy
1,746
+182
+12% +$14.6K ﹤0.01% 5475
2019
Q1 		$137K Sell
1,564
-7,157
-82% -$793K ﹤0.01% 5455
2018
Q4 		$1.23M Buy
8,721
+8,009
+1,125% +$1.35M ﹤0.01% 3191
2018
Q3 		$182K Sell
712
-2,752
-79% -$761K ﹤0.01% 5357
2018
Q2 		$882K Buy
3,464
+2,042
+144% +$505K ﹤0.01% 3490
2018
Q1 		$286K Buy
1,422
+1,186
+503% +$236K ﹤0.01% 4577
2017
Q4 		$34K Buy
236
+119
+102% +$19.1K ﹤0.01% 6431
2017
Q3 		$19K Buy
117
+111
+1,850% +$15.9K ﹤0.01% 6458
2017
Q2 		$1K Sell
6
-50
-89% -$7.4K ﹤0.01% 7167
2017
Q1 		$11K Buy
56
+14
+33% +$2.25K ﹤0.01% 6523
2016
Q4 		$6K Hold
42
– – ﹤0.01% 6873
2016
Q3 		$6K Sell
42
-194
-82% -$23.3K ﹤0.01% 6714
2016
Q2 		$24K Sell
236
-937
-80% -$122K ﹤0.01% 6044
2016
Q1 		$157K Sell
1,173
-115
-9% -$12.7K ﹤0.01% 5311
2015
Q4 		$256K Buy
1,288
+585
+83% +$127K ﹤0.01% 4512
2015
Q3 		$111K Sell
703
-263
-27% -$70.3K ﹤0.01% 4902
2015
Q2 		$395K Sell
966
-40
-4% -$17.3K ﹤0.01% 3926
2015
Q1 		$462K Buy
1,006
+395
+65% +$170K ﹤0.01% 3813
2014
Q4 		$343K Buy
611
+556
+1,011% +$316K ﹤0.01% 4230
2014
Q3 		$29K Buy
55
+48
+686% +$27.1K ﹤0.01% 5662
2014
Q2 		$5K Sell
7
-4
-36% -$1.86K ﹤0.01% 6462
2014
Q1 		$5K Sell
11
-244
-96% -$124K ﹤0.01% 6590
2013
Q4 		$88K Buy
+255
New +$70.4K ﹤0.01% 5336

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup's KPTI Position: Q1 2026 in Review

Citigroup increased its Karyopharm Therapeutics (KPTI) stake by 494,000% in Q1 2026, buying an estimated $37.7K and bringing the position to 4,941 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4734.

Citigroup first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $4.01M in Q2 2021. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Citigroup held 4,941 shares of Karyopharm Therapeutics worth $27.5K as of Q1 2026.
  • Citigroup bought 4,940 Karyopharm Therapeutics shares in Q1 2026, an estimated $37.7K.
  • Karyopharm Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4734 holding.
  • Citigroup first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Citigroup's Karyopharm Therapeutics position peaked at $4.01M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.